| Nov 15 |
Q1 2025 Palatin Technologies Inc Earnings Call
|
| Nov 15 |
Palatin Technologies Inc (PTN) Q1 2025 Earnings Call Highlights: Strategic Shifts Amid Revenue ...
|
| Nov 14 |
Palatin Technologies, Inc. (PTN) Q1 2025 Earnings Conference Call Transcript
|
| Nov 14 |
Palatin Technologies GAAP EPS of -$0.39 beats by $0.12
|
| Nov 14 |
Palatin Reports First Quarter Fiscal Year 2025 Operating/Financial Results
|
| Nov 14 |
Earnings Scheduled For November 14, 2024
|
| Nov 13 |
Palatin Technologies Q1 2025 Earnings Preview
|
| Nov 8 |
Palatin to Report First Quarter Fiscal Year 2025 Results; Teleconference and Webcast to be held on November 14, 2024
|
| Nov 4 |
Palatin Presents Data on Novel Melanocortin 4 Receptor Selective Oral Small Molecule PL7737 Obesity Program at ObesityWeek® 2024
|
| Oct 31 |
Palatin Completes Enrollment in Phase 2 Clinical Study of Bremelanotide (MC4R Agonist) Co-Administered with Tirzepatide (GLP-1/GIP) for the Treatment of Obesity
|
